Neutropenia and febrile neutropenia (FN) are common complications of myelosuppressive
chemotherapy. This review provides an up-to-date assessment of the patient and cost …

Highlights•Cancer care has been profoundly impacted by the global pandemic of COVID-19,
resulting in unprecedented challenges.•Oncology societies have updated guidelines for the …

Background and objective: Best-value biological medicines may generate competition in the
off-patent biologicals market, resulting in having more resources available to provide …

Purpose Clinical practice guidelines recommend the use of all approved granulocyte colony-
stimulating factors (G-CSFs), including filgrastim and pegfilgrastim, as primary febrile …

Introduction Approved biosimilars exhibit comparable efficacy, safety, and immunogenicity to
reference products. This report provides perspectives on the societal value of biosimilars …

Granulocyte colony-stimulating factor (G-CSF) biologics, such as pegfilgrastim, are a
standard of care in supportive cancer treatment that are administered once per …

Data about biosimilar Peg-filgrastim (bioPEG) in autologous stem cell transplant (ASCT) are
still scarce. The aim of this study has been to assess efficacy and safety of bioPEG among …

Background: Real-world data suggests superiority of pegfilgrastim (PEG) over filgrastim (FIL)
in reducing the incidence of chemotherapy-induced febrile neutropenia (FN), probably …

Background: Febrile neutropaenia (FN) and resultant infections are the major cause of
treatment-related morbidity and mortality in patients receiving chemotherapy. Clinical …

Tumor cells are particularly adept at exploiting the immunosuppressive potential of
neutrophils as a strategy to achieve uncontrolled proliferation and spread. Recruitment of …